This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Cardiovascular Diabetology
JULY 22, 2024
Heart failure with preserved ejection fraction (HFpEF) is a mortal clinical syndrome without effective therapies. Empagliflozin (EMPA) improves cardiovascular outcomes in HFpEF patients, but the underlying mec.
Cardiovascular Diabetology
AUGUST 13, 2024
Heart failure with preserved ejection fraction (HFpEF) is associated with systemic inflammation, obesity, metabolic syndrome, and gut microbiome changes. Increased trimethylamine-N-oxide (TMAO) levels are pred.
Medical Xpress - Cardiology
JULY 29, 2024
A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
American College of Cardiology
MARCH 31, 2025
25 in Chicago and simultaneously published in JACC.
American Heart News - Heart News
JULY 24, 2024
Research Highlights: In mice with heart failure with preserved ejection fraction (HFpEF), increasing ketone supply to the heart allowed their hearts to utilize more ketones and produce more energy. Researchers hope this study may help to improve our.
Cardiovascular Diabetology
MARCH 21, 2025
Heart failure (HF) with preserved ejection fraction (HFpEF) is increasingly prevalent worldwide due to aging and comorbidities. Epicardial adipose tissue (EAT), favored by diabetes and obesity, was shown to co.
Frontiers in Cardiovascular Medicine
JANUARY 7, 2024
Heart failure with preserved ejection fraction (HFpEF) is the largest unmet clinical need in cardiovascular medicine. Despite decades of research, the treatment option for HFpEF is still limited, indicating our ongoing incomplete understanding on the underlying molecular mechanisms.
Cardiovascular Diabetology
NOVEMBER 4, 2024
Aging is influenced by genetic determinants and comorbidities, among which diabetes increases the risk for heart failure with preserved ejection fraction. There is no therapy to prevent heart dysfunction in ag.
Heart BMJ
FEBRUARY 12, 2025
Cardiomyopathy is a primary determinant of prognosis in FD and typically presents as a heart failure (HF) with a preserved ejection fraction phenotype. 4 Indeed, the use of CPET is recognised in HF guidelines 5 and parameters such as peak oxygen consumption (VO 2peak ) offer a.
52 
DAIC
JULY 31, 2024
mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
111 
Cardiovascular Diabetology
AUGUST 30, 2024
Heart failure with preserved ejection fraction (HFpEF) is common in type 2 diabetes mellitus (T2D), leading to high morbidity and mortality. Managing HFpEF in diabetic patients is challenging with limited trea.
The New England Journal of Medicine
AUGUST 31, 2024
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 European Society of Cardiology annual meeting.
Medical Xpress - Cardiology
JULY 24, 2024
Increasing ketone supply to the heart in mice with heart failure with preserved ejection fraction (HFpEF) allowed their hearts to utilize more ketones and produce more energy, according to preliminary research presented today at the American Heart Association's Basic Cardiovascular Sciences Scientific Sessions 2024.
European Journal of Heart Failure
FEBRUARY 25, 2025
Differences in heart failure with preserved ejection fraction (HFpEF) management across medical specialties. A large majority of HFpEF patients are cared by non-cardiologists.
European Journal of Heart Failure
OCTOBER 30, 2023
2–4 points denotes an intermediate risk for heart failure with preserved ejection fraction (HFpEF) at non-invasive testing at rest. Abstract Aims Pulmonary capillary wedge pressure (PAWP) ≥25 mmHg during bicycle ergometry is recommended to uncover occult heart failure with preserved ejection fraction.
European Journal of Heart Failure
OCTOBER 30, 2023
In patients with heart failure with preserved ejection fraction (HFpEF), abnormal global longitudinal strain (GLS) is a strong predictor for clinical events and can help identity patients who are at risk for future decline in left ventricular ejection fraction (LVEF).
European Journal of Heart Failure
DECEMBER 28, 2023
Abstract Aims Preventive strategies for heart failure (HF) with preserved ejection fraction (HFpEF) include pharmacotherapies and lifestyle modifications. Thus, we evaluated the association between CRF and HFpEF incidence.
Nature Reviews - Cardiology
AUGUST 27, 2024
Nature Reviews Cardiology, Published online: 28 August 2024; doi:10.1038/s41569-024-01067-1 The pathophysiology of heart failure with preserved ejection fraction (HFpEF) remains poorly understood.
Frontiers in Cardiovascular Medicine
JANUARY 26, 2025
This proof-of-principle study investigates the association between tissue sodium content, assessed by MRI, and HF-related baseline parameters in an outpatient cohort of patients with chronic heart failure, including those with reduced ejection fraction (HFrEF), mildly reduced ejection fraction (HFmrEF), and preserved ejection fraction (HFpEF).Methods
Circulation
NOVEMBER 11, 2024
Background:Heart failure (HF) with preserved ejection fraction (HFpEF) is a complex syndrome characterized by heterogeneous pathophysiology and dynamic changes in cardiac structure and function. Circulation, Volume 150, Issue Suppl_1 , Page A4121812-A4121812, November 12, 2024.
European Journal of Heart Failure
DECEMBER 7, 2023
Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF).
DAIC
JUNE 21, 2024
announced that the peer-reviewed Journal of the American College of Cardiology: Heart Failure has published a research paper concluding that INPEFA (sotagliflozin) is cost-effective for people with diabetes and recent worsening heart failure using commonly accepted willingness-to-pay thresholds. “Our healthcare system.
105 
Circulation
NOVEMBER 11, 2024
As heart failure with preserved ejection fraction (HFpEF) comprises half of all heart failure cases, understanding its management and effect on outcomes is crucial. Further research is needed to understand the impact of chronic opioid use on HFpEF patients.
European Journal of Heart Failure
DECEMBER 28, 2023
Abstract Background and aim Heart Failure with preserved Ejection Fraction (HFpEF) remains under-diagnosed in clinical practice despite accounting for nearly half of all Heart Hailure (HF) cases. Accurate and timely diagnosis of HFpEF is crucial for proper patient management and treatment.
European Journal of Heart Failure
MARCH 11, 2024
Abstract Aims The aim of this study was to assess the pathophysiological implications of severe tricuspid regurgitation (TR) in patients with heart failure with preserved ejection fraction (HFpEF) by using tricuspid transcatheter edge-to-edge repair (T-TEER) as a model of right ventricular (RV) volume overload relief.
The New England Journal of Medicine
NOVEMBER 15, 2024
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 American Heart Association Scientific Sessions.
European Journal of Heart Failure
MARCH 4, 2024
Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. CI, confidence interval; HR, hazard ratio. Aims Lower respiratory tract infections (LRTI) are common worldwide.
Cardiovascular Diabetology
FEBRUARY 12, 2024
However, its implications specifically in HF with preserved ejection fr. Recent studies highlighted that stress hyperglycemia ratio (SHR) is a potential predictor for future risk in heart failure (HF) patients.
Cardiovascular Diabetology
AUGUST 15, 2024
Patients with diabetes have an increased risk of developing heart failure with preserved ejection fraction (HFpEF). This study aimed to compare indices of myocardial deformation and perfusion between patients.
Cardiovascular Diabetology
OCTOBER 18, 2024
Type 2 diabetes mellitus (T2DM) is a major risk factor for heart failure with preserved ejection fraction and cardiac arrhythmias. Precursors of these complications, such as diabetic cardiomyopathy, remain inc.
Cardiovascular Diabetology
SEPTEMBER 10, 2024
Although the “obesity paradox” is comprehensively elucidated in heart failure (HF) with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), the role of body composition in left v.
HeartRhythm
APRIL 30, 2024
Overtime, various studies have reported variable mortality outcomes in heart failure with preserved ejection fraction (HFpEF) patients. It remains unclear to what extent atrial fibrillation (AF) creates increased mortality alone or in combination with either HFpEF or heart failure with reduced ejection fraction (HFrEF).
Frontiers in Cardiovascular Medicine
FEBRUARY 6, 2024
Objectives The aim of this retrospective study was to explore the diagnostic potential of various cardiac parameters in differentiating between heart failure with preserved ejection fraction (HFpEF) and heart failure with mid-ranged and reduced ejection fraction (HFm + rEF), and to discern their relationship with normal cardiac function.
HeartRhythm
APRIL 30, 2024
Studies have shown an overriding benefit of AF ablation in patients with long-standing HFrEF and symptomatic AF. Any benefit from active AF intervention in patients with HFpEF has been less certain.
European Journal of Heart Failure
MARCH 30, 2025
We assessed the associations of MetS indices with echocardiographic parameters, biomarkers of myocardial damage (high-sensitivity cardiac troponin I [hs-cTnI] and B-type natriuretic peptide [BNP]) and incident HF hospitalizations including HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF).
DAIC
FEBRUARY 29, 2024
Five highly-anticipated late-breaking clinical trial sessions, an ACC/AHA guidelines update session and a host of featured clinical research sessions have been announced by program planners for the American College of Cardiology’s 73 rd Annual Scientific Session & Expo to be held April 6-8 in Atlanta, GA.
103 European Journal of Heart Failure
MARCH 19, 2025
Abstract Aims Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promising effects in reducing cardiovascular events in patients with obesity and heart failure (HF) with preserved ejection fraction (HFpEF) irrespective of concomitant diabetes.
European Journal of Heart Failure
FEBRUARY 5, 2025
Meta-analysis on the main outcomes of angiotensin receptorneprilysin inhibitor (ARNI) in heart failure (HF) patients with end-stage kidney disease (ESKD) on dialysis.
Circulation
NOVEMBER 11, 2024
Intro:Drug Development for Heart failure with Preserved Ejection Fraction (HFpEF) is a major challenge facing cardiovascular research due to its complex pathophysiology and existence of comorbidities, leading to recognize distinct HFpEF phenogroups.
European Journal of Heart Failure
OCTOBER 17, 2023
HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction. Associations of colchicine-related plasma proteins, incident heart failure (HF) and cardiac structure and function.
European Journal of Heart Failure
DECEMBER 20, 2023
Abstract Introduction Emerging evidence suggests a beneficial effect of higher heart rates in some patients with heart failure with preserved ejection fraction (HFpEF).
European Journal of Heart Failure
DECEMBER 13, 2023
Abstract Aim Epicardial adipose tissue (EAT) plays a role in obesity-related heart failure with preserved ejection fraction. BMI, body mass index; GLS, global longitudinal strain; LASct, left atrial contractile strain.
40 
European Journal of Heart Failure
NOVEMBER 8, 2023
Abstract Aim To examine the ability of serum proteins in predicting future heart failure (HF) events, including HF with reduced or preserved ejection fraction (HFrEF or HFpEF), in relation to event time, and with or without considering established HF-associated clinical variables.
European Journal of Heart Failure
APRIL 13, 2025
The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content